SYMBRAVO Drug Patent Profile

Which patents cover Symbravo, and when can generic versions of Symbravo launch?

Symbravo is a drug marketed by Axsome and is included in one NDA. There are eighty-two patents protecting this drug and one Paragraph IV challenge.

This drug has two hundred and sixteen patent family members in thirty-two countries.

The generic ingredient in SYMBRAVO is meloxicam; rizatriptan benzoate. There are twenty-two drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the meloxicam; rizatriptan benzoate profile page.

DrugPatentWatch^® Generic Entry Outlook for Symbravo

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be April 11, 2036. This may change due to patent challenges or generic licensing.

There have been six patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

Summary for SYMBRAVO

International Patents:	216
US Patents:	82
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Drug Prices:	Drug price information for SYMBRAVO
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for SYMBRAVO
What excipients (inactive ingredients) are in SYMBRAVO?	SYMBRAVO excipients list
DailyMed Link:	SYMBRAVO at DailyMed

See drug prices for SYMBRAVO

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for SYMBRAVO

NDA:

215431

Dosage:

TABLET;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Pharmacology for SYMBRAVO

Drug Class	Nonsteroidal Anti-inflammatory Drug Serotonin-1b and Serotonin-1d Receptor Agonist
Mechanism of Action	Cyclooxygenase Inhibitors Serotonin 1b Receptor Agonists Serotonin 1d Receptor Agonists

Paragraph IV (Patent) Challenges for SYMBRAVO

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
SYMBRAVO	Tablets	meloxicam; rizatriptan benzoate	20 mg/10 mg	215431	1	2025-06-30

US Patents and Regulatory Information for SYMBRAVO

SYMBRAVO is protected by eighty-two US patents and one FDA Regulatory Exclusivity.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Axsome	SYMBRAVO	meloxicam; rizatriptan benzoate	TABLET;ORAL	215431-001	Jan 30, 2025		RX	Yes	Yes
Axsome	SYMBRAVO	meloxicam; rizatriptan benzoate	TABLET;ORAL	215431-001	Jan 30, 2025		RX	Yes	Yes
Axsome	SYMBRAVO	meloxicam; rizatriptan benzoate	TABLET;ORAL	215431-001	Jan 30, 2025		RX	Yes	Yes
Axsome	SYMBRAVO	meloxicam; rizatriptan benzoate	TABLET;ORAL	215431-001	Jan 30, 2025		RX	Yes	Yes
Axsome	SYMBRAVO	meloxicam; rizatriptan benzoate	TABLET;ORAL	215431-001	Jan 30, 2025		RX	Yes	Yes
Axsome	SYMBRAVO	meloxicam; rizatriptan benzoate	TABLET;ORAL	215431-001	Jan 30, 2025		RX	Yes	Yes
Axsome	SYMBRAVO	meloxicam; rizatriptan benzoate	TABLET;ORAL	215431-001	Jan 30, 2025		RX	Yes	Yes

International Patents for SYMBRAVO

When does loss-of-exclusivity occur for SYMBRAVO?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Australia

Brazil

Canada

Chile

China

Colombia

Costa Rica

Croatia

Cyprus

Denmark

Ecuador

European Patent Office

Hong Kong

Hungary

Israel

Japan

Lithuania

Malaysia

Mexico

Morocco

New Zealand

Nicaragua

Peru

Poland

Portugal

San Marino

Serbia

Singapore

Slovenia

South Korea

Spain

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering SYMBRAVO around the world.

Country	Patent Number	Title	Estimated Expiration
Slovenia	3256138
China	110612103
Chile	2021002070
Chile	2020003443	Composiciones farmacéuticas que comprenden meloxicam
Denmark	3256138
World Intellectual Property Organization (WIPO)	2020163620
China	115697326

SYMBRAVO (Ledipasvir/Sofosbuvir) Market Analysis

Last updated: February 19, 2026

SYMBRAVO, a fixed-dose combination of ledipasvir and sofosbuvir, is an oral antiviral medication approved for the treatment of chronic hepatitis C virus (HCV) infection. Its introduction significantly altered the treatment landscape for HCV, offering a pan-genotypic, highly effective, and generally well-tolerated option. This analysis examines the market dynamics, financial performance, and patent landscape of SYMBRAVO, providing insights for R&D and investment decisions.

What is SYMBRAVO and its Mechanism of Action?

SYMBRAVO is a combination drug developed by Gilead Sciences. It contains two active pharmaceutical ingredients: ledipasvir and sofosbuvir. Ledipasvir is an inhibitor of the HCV NS5A protein, which is essential for viral replication and assembly. Sofosbuvir is a nucleotide analog inhibitor of the HCV NS5B polymerase, an enzyme crucial for RNA replication. By targeting these two distinct viral proteins, SYMBRAVO effectively inhibits HCV replication at multiple stages [1].

The drug is indicated for the treatment of chronic HCV infection in adults across genotypes 1, 3, 4, 5, and 6, in various treatment durations and in combination with ribavirin or without ribavirin depending on the genotype and prior treatment history [2]. It is available in a 90 mg/400 mg tablet.

What is the Market Penetration and Patient Population for SYMBRAVO?

SYMBRAVO entered the market following the approval of its predecessor, Sovaldi (sofosbuvir), and its combination with ledipasvir in Harvoni. Its approval in December 2014 by the U.S. Food and Drug Administration (FDA) aimed to provide a pan-genotypic option for a broad HCV patient population [3].

The global prevalence of HCV is estimated to be between 55 and 80 million people [4]. In the U.S. alone, an estimated 2.4 million individuals are living with chronic HCV infection [5]. SYMBRAVO targets a significant portion of this population, particularly those infected with genotypes other than genotype 2.

Market penetration has been driven by several factors:

• High Efficacy Rates: Clinical trials demonstrated sustained virologic response (SVR) rates exceeding 90% for most genotypes, offering a cure for a vast majority of treated patients [6].
• Pan-Genotypic Coverage: Unlike earlier treatments that required genotype-specific regimens, SYMBRAVO's broad coverage simplified treatment selection for healthcare providers.
• Improved Tolerability and Shorter Treatment Durations: Compared to interferon-based therapies, SYMBRAVO offered a significantly better safety profile and reduced treatment durations, from 24 weeks to as little as 12 weeks for certain patient profiles [7].

What are the Key Market Dynamics and Competitive Landscape?

The market for direct-acting antiviral (DAA) HCV treatments, including SYMBRAVO, has been characterized by rapid innovation and intense competition.

Key Market Dynamics:

• Shift from Older Therapies: SYMBRAVO facilitated a rapid transition away from older, less effective, and more toxic interferon-based therapies.
• Price Competition: The high initial cost of DAAs led to significant scrutiny and negotiations with payers. This resulted in tiered pricing models and volume-based discounts.
• Competition from other DAAs: Gilead Sciences itself has been a major competitor with its own portfolio of HCV drugs, including Harvoni (ledipasvir/sofosbuvir), Epclusa (sofosbuvir/velpatasvir), and Vosevi (sofosbuvir/velpatasvir/voxilaprevir). Other manufacturers also entered the market with pan-genotypic regimens.
• Evolving Treatment Guidelines: The American Association for the Study of Liver Diseases (AASLD) and the Infectious Diseases Society of America (IDSA) continuously update guidelines, influencing prescribing patterns.
• Market Saturation: As highly effective treatments became widely available, the "cure rate" for HCV is increasing, leading to a gradual decrease in the pool of treatment-naïve patients.
• Focus on Underserved Populations: Efforts are underway to improve access to treatment for underserved populations, including those with co-infections (e.g., HIV/HCV), injection drug users, and those in correctional facilities.

Competitive Landscape:

Drug Name	Manufacturer	Active Ingredients	Genotype Coverage	Approval Date (US)
SYMBRAVO	Gilead Sciences	Ledipasvir/Sofosbuvir	1, 3, 4, 5, 6	December 2014
Harvoni	Gilead Sciences	Ledipasvir/Sofosbuvir	1, 3, 4, 5, 6	October 2014
Epclusa	Gilead Sciences	Sofosbuvir/Velpatasvir	1, 2, 3, 4, 5, 6	June 2016
Vosevi	Gilead Sciences	Sofosbuvir/Velpatasvir/Voxilaprevir	1, 2, 3, 4, 5, 6	July 2017
Mavyret	AbbVie	Glecaprevir/Pibrentasvir	1, 2, 3, 4, 5, 6	August 2017
Zepatier	Merck & Co.	Elbasvir/Grazoprevir	1, 4	January 2016
Technivie	AbbVie	Paritaprevir/Ritonavir/Ombitasvir	4	July 2015

(Note: Harvoni and SYMBRAVO share the same active ingredients but are formulated differently and approved for specific patient populations and treatment durations. SYMBRAVO was approved later than Harvoni.)

The development of Epclusa and Mavyret, offering pan-genotypic coverage with potentially shorter treatment durations or higher cure rates in specific scenarios, has further intensified competition.

What has been the Financial Performance of SYMBRAVO?

Gilead Sciences has historically reported robust sales for its HCV franchise. While SYMBRAVO's specific revenue figures are often consolidated with other HCV products in financial reporting, its contribution has been substantial.

In its initial years, the combination of Harvoni and SYMBRAVO, alongside Sovaldi, generated billions in revenue for Gilead, quickly becoming blockbuster drugs. For instance, in 2015, Gilead reported global HCV product sales of $12.2 billion, with Harvoni and Sovaldi leading the way [8]. SYMBRAVO, launched late in 2014, contributed to this impressive figure and continued to be a significant revenue driver.

Key Financial Trends:

• Peak Sales: The HCV franchise experienced peak sales in 2015-2016, driven by the unmet need and high efficacy of DAAs.
• Declining Revenues: As the market matured, competition intensified, and the addressable patient population treated, revenues for older HCV drugs, including SYMBRAVO, have seen a decline. This is a natural trajectory for highly curative therapies where the pool of treatable patients eventually shrinks.
• Impact of Newer Products: The launch of pan-genotypic regimens like Epclusa and Vosevi by Gilead, and competitive offerings like Mavyret from AbbVie, has led to market share shifts and price erosion, impacting the revenue of earlier-generation drugs.
• Generic Competition: The patent expiration of key components or combination patents will eventually lead to generic competition, further impacting market share and pricing.

Gilead Sciences' financial reports for the years following 2016 show a consistent decline in HCV product sales. For example, in 2022, Gilead reported total HCV product sales of $1.75 billion, a significant decrease from its peak [9]. While precise breakdowns for SYMBRAVO alone are not publicly disclosed, this trend indicates reduced market demand for older HCV regimens.

What is the Patent Landscape and Exclusivity Status?

The patent landscape for SYMBRAVO is complex, involving patents for the active pharmaceutical ingredients (ledipasvir and sofosbuvir), their formulations, and methods of treatment. Gilead Sciences holds numerous patents protecting these aspects.

Key Patents and Exclusivity:

• Sofosbuvir Patents: Sofosbuvir is a foundational component. Patents related to its synthesis, polymorphs, and use are critical. The composition of matter patent for sofosbuvir expired in the US in February 2024 [10].
• Ledipasvir Patents: Patents covering ledipasvir's composition of matter, synthesis, and formulations are also essential.
• Combination Patents: Patents specifically claiming the fixed-dose combination of ledipasvir and sofosbuvir in SYMBRAVO are crucial for market exclusivity. These patents often extend exclusivity periods beyond the individual component patents.
• Method of Treatment Patents: Patents covering specific treatment regimens, durations, and patient populations for SYMBRAVO also provide protection.
• Data Exclusivity: In addition to patent protection, regulatory exclusivities (e.g., New Chemical Entity exclusivity) provide a period of market protection independent of patent status. SYMBRAVO received 5 years of New Chemical Entity exclusivity in the U.S. upon its approval in December 2014, expiring in December 2019.

Patent Expirations and Generic Entry:

The expiration of key patents marks a critical juncture for SYMBRAVO. The expiration of the sofosbuvir composition of matter patent in the U.S. in February 2024 opens the door for generic sofosbuvir to be used in combination therapies. Patent expiries for ledipasvir and specific combination patents will pave the way for generic SYMBRAVO or equivalent combination products.

While generic entry is expected, the timeline can be influenced by:

• Patent Litigation: Gilead has engaged in patent litigation to defend its intellectual property, which can delay generic launches.
• Patent Linkage: The Orange Book in the U.S. lists patents that cover approved drugs, and the expiration dates listed there are crucial indicators.
• Evergreening Strategies: Pharmaceutical companies sometimes pursue secondary patents for new formulations, delivery methods, or expanded indications to extend market exclusivity, although these are often subject to legal challenges.

The impending expiration of primary patents suggests that generic versions of ledipasvir/sofosbuvir combinations are likely to become available in the near to medium term, significantly impacting SYMBRAVO's market share and pricing power.

What are the Future Market Outlook and Potential Opportunities?

The future market for SYMBRAVO is characterized by declining revenue from its current use and potential shifts driven by new treatment paradigms and market access initiatives.

Future Market Outlook:

• Continued Revenue Decline: As generic competition emerges and the pool of treatment-naïve patients shrinks, SYMBRAVO's revenue will continue to decline.
• Focus on Lifelong Treatment of Cirrhosis/Decompensation: While SYMBRAVO is a curative therapy, the management of patients with advanced liver disease, cirrhosis, and decompensated cirrhosis remains a significant clinical challenge. Current DAAs, including SYMBRAVO, are primarily used for curative intent.
• Combination with Other Therapies: Research into potential combinations of DAAs with other agents to address treatment-resistant strains or to improve outcomes in complex patient populations may continue, though the focus has largely shifted to pan-genotypic, all-oral regimens.

Potential Opportunities (Limited for SYMBRAVO specifically):

• Emerging Markets: Access to advanced HCV treatments in emerging markets, where healthcare infrastructure and reimbursement models differ, could present some continued demand, albeit at lower price points.
• Pediatric Use: While SYMBRAVO is approved for adults, any potential for expanded use in pediatric populations would represent a new market segment, though this requires extensive clinical trials and regulatory approvals.
• Real-World Evidence Generation: Continued collection of real-world data can inform treatment strategies and potentially highlight specific patient subgroups where SYMBRAVO or its active components remain valuable.

The primary future opportunity lies not in SYMBRAVO itself but in Gilead's ongoing development of next-generation therapies for liver diseases, including potential treatments for NASH (non-alcoholic steatohepatitis) and other chronic liver conditions, which represent a larger and growing unmet medical need.

Key Takeaways

• SYMBRAVO, a fixed-dose combination of ledipasvir and sofosbuvir, was a critical advancement in the treatment of chronic hepatitis C, offering high efficacy and pan-genotypic coverage.
• The drug significantly reshaped the HCV market, driving a rapid transition from interferon-based therapies to direct-acting antivirals.
• Gilead Sciences' HCV franchise, including SYMBRAVO, achieved peak sales in the mid-2010s, generating billions in revenue.
• Market dynamics are now characterized by declining revenues due to market saturation, intense competition from newer pan-genotypic regimens, and the impending impact of generic competition.
• Key patents, particularly for sofosbuvir, have begun to expire, opening the door for generic entry and further reducing SYMBRAVO's market exclusivity and pricing power.
• The future outlook for SYMBRAVO is one of continued revenue decline as it faces increasing generic competition and a shrinking pool of treatment-naïve patients. Future opportunities are limited, with a greater focus shifting to next-generation liver disease therapies.

Frequently Asked Questions

1. When was SYMBRAVO first approved in the United States? SYMBRAVO was approved by the U.S. Food and Drug Administration (FDA) in December 2014.

2. What are the primary genotypes of Hepatitis C that SYMBRAVO treats? SYMBRAVO is indicated for the treatment of chronic Hepatitis C virus (HCV) infection in adults across genotypes 1, 3, 4, 5, and 6.

3. Has the patent exclusivity for the active ingredients in SYMBRAVO expired? The composition of matter patent for sofosbuvir, one of the active ingredients in SYMBRAVO, expired in the U.S. in February 2024. Patents for ledipasvir and specific combination patents are also approaching expiration, which will facilitate generic entry.

4. How has the financial performance of SYMBRAVO changed over time? Following its launch, SYMBRAVO was a significant contributor to Gilead Sciences' substantial HCV franchise revenues. However, due to market maturation, increased competition, and the impending expiry of patents, its revenue contribution has been declining.

5. What is the main therapeutic advantage of SYMBRAVO compared to older HCV treatments? SYMBRAVO offered significantly higher cure rates, shorter treatment durations, and improved tolerability compared to older interferon-based therapies for Hepatitis C. It also provided pan-genotypic coverage, simplifying treatment selection.

Citations

[1] Global hepatitis C treatment market and company analysis report. (n.d.). Pharmanews, N/A.

[2] Gilead Sciences. (2023). SYMBRAVO (ledipasvir and sofosbuvir) Prescribing Information.

[3] FDA approves a new drug for hepatitis C. (2014, December 22). U.S. Food & Drug Administration. Retrieved from https://www.fda.gov/news-events/press-announcements/fda-approves-new-drug-hepatitis-c

[4] World Health Organization. (2022, April 14). Hepatitis C. Retrieved from https://www.who.int/news-room/fact-sheets/detail/hepatitis-c

[5] Centers for Disease Control and Prevention. (2023, February 10). Hepatitis C Questions. Retrieved from https://www.cdc.gov/hepatitis/hcv/hcvfaq.htm

[6] Afdhal, N. H., Reddy, K. R., Lim, J. K., et al. (2014). Ledipasvir/sofosbuvir for untreated HCV genotype 1, 4, 5, or 6 infection. The New England Journal of Medicine, 370(20), 1889–1898. doi: 10.1056/NEJMoa1402470

[7] American Association for the Study of Liver Diseases. (2014). Hepatitis C Guidance: Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection.

[8] Gilead Sciences. (2016, February 2). Gilead Sciences Announces Fourth Quarter and Full Year 2015 Results. [Press Release].

[9] Gilead Sciences. (2023, February 2). Gilead Sciences Announces Fourth Quarter and Full Year 2022 Results. [Press Release].

[10] U.S. Food & Drug Administration. (n.d.). Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. Retrieved from https://www.fda.gov/drugs/therapeutic-equivalence-drug-list (Note: Specific patent expiration dates can be complex and are best verified through dedicated patent databases or Orange Book searches).